Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 17, Issue 28, Pages 3084-3098Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026617666170707124126
Keywords
Anticancer agents; Multi-targeting; Drug development; Precision medicine; BCR-ABL; Cytotoxic anticancer drug
Categories
Funding
- National Natural Science Foundation of China [21135006, 21127901, 21275148, 21301181, 21321003, 21575145]
- National Basic Research Program of China (973 Program of MOST) [2013CB531805]
Ask authors/readers for more resources
There is a great demand for the development of novel anticancer drugs, due to the increasing morbidity and high mortality of cancer. To date, chemotherapy still plays a central role in the clinical treatment of cancer, but this role is being reduced by targeted therapies. Since cancer is a complicated and multiple genes involved disease, drugs that act at multiple targets can enhance efficacy and lower drug resistance, and are thought to be the future of novel anticancer drug development. In this paper, we discuss the recent development of single molecule, multi-target anticancer agents that combine two or more pharmacophores in a single molecule, including organic multitargeted anticancer agents and metal based complexes such as platinum, ruthenium, iridium and rhodium complexes. These efforts will contribute to clinical cancer therapy and benefit patients in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available